ArticleJournal of natural products2026
Barettin, a Nonopioid, Nonhallucinogenic Marine Natural Product with Antihyperalgesic Properties Mediated by 5HT2A Inverse Agonism.
Article in Journal of natural products, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Barettin Suppresses Pancreatic Ductal Adenocarcinoma Proliferation via Topoisomerase IIα Inhibition.Marine drugs · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite increasing interest, there remain limited treatments for chronic pain, with opioids continuing to be one of the top prescribed medications. Marine natural products present a wealth of untapped potential for new treatments for chronic pain. In this study, we investigated the analgesic effects of the sea sponge ligand barettin in a mouse model of chemotherapy-induced peripheral neuropathy (CIPN). Barettin exhibited efficacious antihyperalgesic activity in male mice with no efficacy shown in females. Through the use of a PRESTO-Tango assay, we found that barettin acts as an inverse agonist at the 5HT2A receptor while also presenting no activity at the μ-opioid receptor. Head twitch experiments confirmed no hallucinogenic activity, suggesting that barettin may be a promising nonopioid, nonhallucinogenic, marine-derived therapeutic agent for the treatment of chronic pain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.